KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Restructuring Costs (2016 - 2025)

Pfizer (PFE) has disclosed Restructuring Costs for 17 consecutive years, with $259.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Restructuring Costs fell 76.19% to $259.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 54.86% decrease, with the full-year FY2025 number at $1.1 billion, down 54.86% from a year prior.
  • Restructuring Costs was $259.0 million for Q4 2025 at Pfizer, down from $286.0 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $2.6 billion in Q4 2023 to a low of -$131.0 million in Q2 2025.
  • A 5-year average of $413.9 million and a median of $177.0 million in 2022 define the central range for Restructuring Costs.
  • Peak YoY movement for Restructuring Costs: skyrocketed 14800.0% in 2022, then plummeted 111.87% in 2025.
  • Pfizer's Restructuring Costs stood at $667.0 million in 2021, then tumbled by 70.16% to $199.0 million in 2022, then skyrocketed by 1189.45% to $2.6 billion in 2023, then plummeted by 57.6% to $1.1 billion in 2024, then plummeted by 76.19% to $259.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Restructuring Costs are $259.0 million (Q4 2025), $286.0 million (Q3 2025), and -$131.0 million (Q2 2025).